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Abstract
Here, we show that miR-515-5p inhibits cancer cell migration and
metastasis. RNA-seq analyses of both oestrogen receptor receptor-
positive and receptor-negative breast cancer cells overexpressing
miR-515-5p reveal down-regulation of NRAS, FZD4, CDC42BPA,
PIK3C2B and MARK4 mRNAs. We demonstrate that miR-515-5p inhi-
bits MARK4 directly 30 UTR interaction and that MARK4 knock-down
mimics the effect of miR-515-5p on breast and lung cancer cell
migration. MARK4 overexpression rescues the inhibitory effects of
miR-515-5p, suggesting miR-515-5p mediates this process through
MARK4 down-regulation. Furthermore, miR-515-5p expression is
reduced in metastases compared to primary tumours derived from
both in vivo xenografts and samples from patients with breast
cancer. Conversely, miR-515-5p overexpression prevents tumour cell
dissemination in a mouse metastatic model. Moreover, high miR-
515-5p and low MARK4 expression correlate with increased breast
and lung cancer patients’ survival, respectively. Taken together,
these data demonstrate the importance of miR-515-5p/MARK4 regu-
lation in cell migration and metastasis across two common cancers.
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Introduction
Initially termed MARKL1 (microtubule affinity-regulating kinase-like
1), MARK4 was identified by a cDNA microarray approach to be
down-regulated following a decrease in TCF/LEF1 (transcription
complex, T-cell factor/lymphoid enhancer-binding factor) activity in
hepatocellular carcinoma cell lines. To date, MARK4 expression has
been found to be increased in hepatocellular carcinomas and
gliomas, suggesting a role for MARK4 in cancer development [1,2].
Using a tandem affinity purification approach, MARK4 was found to
interact with a number of proteins linked to the regulation of cell
motility, namely 14-3-3 proteins, ARHGEF2 (GEF-H1)—a micro-
tubule-associated exchange factor for Rho GTPases and phosphatase
2A (PP2A), and was previously shown to dephosphorylate TAU and
other MAPs controlling their microtubule-binding affinity [3,4]. The
identification of these binding partners and MARK4’s interaction
with three forms of tubulin (a-, b-, c-tubulin), myosin and actin
suggest a clear role for MARK4 in control of the cytoskeleton [5,6].
However, nothing is known about the control of MARK4 expression
by, for example, microRNAs.
MicroRNAs (miRNAs) are small non-coding RNAs that post-
transcriptionally regulate gene expression through binding to the
30 UTR of their mRNA targets. In 2009, it was shown that more than
50% of known miRNA target genes are located in cancer-associated
genomic regions (CAGRs), regions in the genome that are frequently
altered in various cancers [7]. Therefore, unsurprisingly, the expres-
sion of miRNAs is often altered among different cancer sub-types
and assessment of the expression of certain miRNAs has allowed for
the accurate differentiation between benign and malignant tissues
[8]. More recently, systemic injection of synthetic tumour suppres-
sor miRNAs has been demonstrated to successfully prevent the
growth of metastases in animal models with cancer metastasis [9].
This evidence suggests that miRNAs-based therapies could be used
to treat metastatic disease or to prevent the formation of metastasis
in early-stage disease.
miR-515-5p was initially described to be a placenta-specific
miRNA involved in foetal growth [10]. However, recently, we iden-
tified its role as a tumour suppressor in breast cancer [11]. We
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demonstrated that miR-515-5p transcription was directly down-
regulated by the oestrogen receptor and that miR-515-5p inhibited
breast cell proliferation by inducing apoptosis [11]. During this
work, a change in MCF-7 and MDA-MB-231 cell morphology was
also observed, a finding that we investigate further here.
Indeed, we show that miR-515-5p overexpression increases
microtubule area not only in breast cancer but also in non-small cell
lung cancer (NSCLC) cells and that this correlates with decreased
cell migration. We performed an RNA-seq following the overexpres-
sion of miR-515-5p in MCF7 and MDA-MB-231 cells, which revealed
the down-regulation of five transcripts linked to cell migration:
NRAS, FZD4, CDC42BPA, PIK3C2B and MARK4 [6,12–15]. These
four transcripts were also down-regulated in A549 and H1299
NSCLC cells in response to miR-515-5p overexpression and luci-
ferase reporter constructs, indicating that miR-515-5p directly regu-
lated NRAS, PIK3C2B and MARK4 expression in multiple cancer
cells. As the strongest down-regulation of expression by miR-515-5p
was seen with MARK4 in both MCF7 and MDA-MB-231 and that this
gene had previously been reported to modulate NSCLC cell motility
[16], we decided to focus our study on investigating the direct regu-
lation of MARK4 expression by miR-515-5p. We showed that
MARK4 silencing reproduces the morphological and cell migration
changes observed following miR-515-5p overexpression in both
breast and NSCLC cells, demonstrating this to be a consistent
phenomenon across two separate tumour types. Conversely, trans-
fection of exogenous MARK4 into miR-515-5p overexpressing cells
rescued the observed decrease in cell migration, suggesting that
MARK4 down-regulation is a crucial mechanism through which
miR-515-5p reduces cell motility. By analysing miR-515-5p expres-
sion in tumour samples derived from breast cancer patients, we
observed its expression to be inversely correlated with metastasis,
while expression of miR-515-5p mimics in A549 NSCLC cells
prevented in vivo tumour cell dissemination in a metastatic mouse
model. In agreement with metastasis being a poorer prognosis factor
for cancer patients, decreased miR-515-5p or increased MARK4
expression was indicative of poorer survival in both metastatic
breast and lung cancer. In short, our data demonstrate that miR-
515-5p dramatically inhibits cell migration by directly down-
regulating MARK4 expression in two different cancer types and
suggests a role for miR-515-5p and MARK4 as potential biomarkers
in metastatic disease and as possible therapeutic targets.
Results
miR-515-5p changes cell morphology and inhibits cell migration
in breast cancer
We initially overexpressed miR-515-5p in breast (MCF7 and MDA-
MD-231) and lung (A549 and H1299) cell lines (Appendix Fig S1A)
and stained for tubulin to assess cell morphology. We observed an
increase in cell area and loss of cell polarity (Fig 1A). The loss of
cell polarity was confirmed quantitatively by comparing the cell
circularity factor of individual cells in 10 fields of view between
control and miR-515-5p overexpressing conditions for the four cell
lines (Appendix Fig S2). Overexpression of miR-515-5p significantly
increased the circularity factor towards a value of 1, indicating loss
of cell elongation.
As cell cytoskeleton dynamics and cell polarity are crucial for cell
motility, we wished to investigate whether this change in morpho-
logy affected cancer cell migration. We analysed the effect of miR-
515-5p overexpression in MDA-MB-231, A549 and H1299 on random
and directional migration by conducting random and Boyden cham-
ber directional cell migration assays. We observed a sharp decrease
in random and directional cell migration in miR-515-5p-transfected
cells as compared to their miRVANA non-targeting controls (NC)
(Fig 1B and C). This however was not the result of overexpression of
this miRNA inducing apoptotic cell death as shown in Appendix Fig
S1B for A549 and H2199 cells and previously published by us for
MDA-MB-231 [11]. Hence, miR-515-5p overexpression is able to
directly suppress cell migration in these cell lines possibly as a
consequence of the observed changes to the cell cytoskeleton.
miR-515-5p directly regulates NRAS, MARK4 and
PIK3C2B expression
To identify which miR-515-5p targets were responsible for its effect
on cancer cell migration, we performed an RNA-seq analysis of MCF7
and MDA-MB-231 cells overexpressing miR-515-5p. Interestingly, we
found 5 down-regulated transcripts which were predicted to interact
with miR-515-5p and have also been implicated in cell migration:
NRAS, FZD4, CDC42BPA, PIK3C2B and MARK4 (Fig 2A, Dataset EV1)
[6,12–15]. To validate the RNA-seq results, we performed valida-
tory qPCRs for the levels of these five transcripts in MCF7 and
MDA-MB-231 cells upon the overexpression of miR-515-5p (Fig 2B
and C) and miR-515-5p sponge vectors (Appendix Fig S3A and B),
which reduce the levels of miR-515-5p by directly interacting with its
mature form. miR-515-5p sponge vectors induced an increase in the
levels of the 5 transcripts in MCF7 but not within MDA-MB-231 cells
(Appendix Fig S3A and B). This is likely to be because miR-515-5p
expression is much lower in MDA-MB-231 than in MCF7 (Appendix
Fig S4). Conversely, we observed a significant down-regulation of the
expression of all five transcripts in the miR-515-5p-transfected MCF7
cells but only a decrease in N-RAS, PI3KC2B and MARK4 mRNA levels
in miR-515-5p-transfected MDA-MB-231 (Fig 2B and C). Interestingly,
miR-515-5p dramatically decreased MARK4 mRNA expression
(> 95%) in both MCF7 and MDA-MB-231 cells (P < 0.001; Fig 2B and
C). Levels of these five transcripts were also decreased in NSCLC cells
(A549 and H1299) upon overexpression of miR-515-5p (although not
significantly for CDC42BPA in A549 cells), underlying a common
molecular function for this miRNA across tumour types (Fig 2D).
We then wished to assess whether the transcripts for N-RAS,
MARK4 and PI3KC2B could be directly regulated by the binding of
miR-515-5p to their 30 UTRs. We used a reporter system where luci-
ferase expression was under the control of the 30 UTRs of our
proposed targets. We showed that miR-515-5p negatively regulated
the levels of luciferase reporter expression in both MCF7 and MDA231
cells by directly interacting with the 30 UTR regions of N-RAS, MARK4
and PI3KC2B (P < 0.001; Fig 2D and E). This demonstrated that the
mRNAs for these three proteins were true direct targets of miR-515-5p.
The specificity of the binding of miR-515-5p to the 30 UTR
regions of MARK4 was demonstrated through mutating both the
sites predicted by TargetScan in the seed sequence. Indeed,
mutation of both sites in the 30 UTR prevented miR-515-5p
from inhibiting luciferase expression from our reporter vector
(Appendix Fig S5).
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Figure 1. miR-515-5p expression changes the tubulin cytoskeleton and inhibits migration of breast and lung cancer cells.
A miR-515-5p expression increases the area of the tubulin cytoskeleton. Tubulin (green) and cell nucleus (blue). Objective x20. Scale bar: 200 lm.
B, C miR-515-5p inhibits random (B) and directed (C) cell migration. The indicated cell lines were transfected with miR-515-5p for 48 h before time-lapse imaging was
performed for 18 h (A), or transwell migration assays were performed for 9 h (C). (B, left panel) Plots show overlays of representative trajectories travelled. (B, right
panel) The distance of migration was quantified and represented as the mean  SEM of values normalised to the respective control condition. n ≥ 30 cells tracked
per condition. (C, left panel) Representative field of view from the bottom of the transwell chambers. Scale bar is 20 lm. (C, right panel) Data represent percentage
of the average number migratory cells per field (n = 5 fields per condition). Data are mean of three experiments  SEM. P-values were calculated by t-test
between miRNA (515-5p) values and their respective non-targeting control miR (NC) values (***P < 0.001). All data shown are representative of experiments
performed at least in triplicate.
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Transcripts Role in migration
N-RAS regulates actin cytoskeletal integrity and cell adhesion
FZD4 induces EMT and loss of cell adhesion
PI3KC2B implicated in the regulation of cell adhesion and actin reorganization
CDC42BPA induces peripheral actin formation and promotes cytoskeletal reorganization
MARK4 involved in the reorganization of microtubules into bundles
Figure 2. miR-515-5p regulates mRNAs involved in cell migration.
A RNA-seq of MCF7 and MDA-MB-231 transfected with miR-515-5p revealed the down-regulation of five transcripts, NRAS, FZD4, CDC42BPA, PIK3C2B and MARK4.
B–D The effect of miR-515-5p overexpression on NRAS, FZD4, CDC42BPA, PIK3C2B and MARK4 mRNA levels in MCF7 (B), MDA-MB-231(C), A549 and H1299 (D) was
determined by qPCR 48 h following transfection of the indicated cell line with non-targeting control miR (NC) or miR-515-5p. Data are displayed as the normalised
mean  SEM of n = 4. P-values were calculated by t-test between miRNA conditions and their respective NC conditions (*P < 0.05; **P < 0.01; ***P < 0.001).
E, F miR-515-5p directly interacts with NRAS, MARK4 and PI3KC2B’s 30 UTR. Relative luciferase activity levels were measured 24 h after co-transfection of MCF-7 (E) and
MDA-MB-231 (F) with 30 UTR-luciferase reporter constructs and either with miR-515-5p or miR-NC. Data shown are normalised mean of three independent
experiments  SEM.
Data information: (B–F) P-values were calculated by t-test between miRNA conditions and their respective NC conditions (*P < 0.05; **P < 0.01; ***P < 0.001).
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Silencing of MARK4 mimics the effect of miR-515-5p on both
random and directional migration
As MARK4 was so predominantly down-regulated by miR-515-5p in
breast cancer cells (Fig 2B and C), we questioned whether silencing
MARK4 would mimic the effect of miR-515-5p on cell morphology
and in cell migration assays. As MCF7 cells are known to display poor
motility, we did not analyse the effect of either miR-515-5p or MARK4
silencing on MCF7 cell migration [17]. Hence, we limited our primary
analysis to MDA-MB-231, A549 and H1299 cell lines. Transfection of
these cell lines with MARK4-targeting siRNAs led to an increase in
the cell area and clustering as can be observed following tubulin
staining (Fig 3A). The change in cell area (quantified in Fig 3A, right
panel) was accompanied by a loss of cell polarity reminiscent of that
observed for miR-515-5p transfection (Fig 1A). We therefore
proceeded to study possible associated changes in cell motility. Our
previously published cell migration screen had revealed that silencing
of MARK4 reduced migration in A549 cells [16], so we used this cell
line as an internal control in these assays. Random migration (RM)
and Boyden chamber directional migration (DM) assays showed that
MARK4 knock-down inhibited cell migration by 48–61%, 55–58%
and 54–56% (RM-DM) in MDA-MB-231, A549 and H1299 cell migra-
tion, respectively (Fig 3B and C). To further validate the role of
MARK4 in the migration of breast cancer cells, we performed random
migration experiments in migratory MDA-157 breast cancer cells and
found that MARK4 silencing significantly reduced their motility
(Appendix Fig S6B). A similar effect was obtained in these cells upon
overexpression of miR-515-5p (Appendix Fig S6B) and was accompa-
nied by changes in cell morphology comparable to that observed in
MDA-MB-231, A549 and H1299 cells (Appendix Fig S6C). Taken
together, these data suggest that MARK4 down-regulation might be
the major cause for the decrease in cell migration observed upon
miR-515-5p overexpression.
miR-515-5p inhibits cell migration through
MARK4 down-regulation
To clarify the importance of MARK4 in the cell migration inhibition
by miR-515-5p, we transfected MDA-MB-231, A549 and H1299 cells
with miR-515-5p, and after 24 h, we overexpressed MARK4 in the
transfected cell lines (Appendix Fig S7A). We then analysed whether
MARK4 overexpression rescued the effect of miR-515-5p on the
random and directional migration of these cell lines (Fig 4A and B).
There was no significant difference between the distance travelled
by MDA-MB-231, A549 and H1299 cells co-overexpressing miR-
515-5p and MARK4 and that of cell lines co-transfected with miR-NC
and empty vector control plasmid (EV) in the random migration
assays (Fig 4A and Appendix Fig S7B). Similarly, in the directional
assay, the expression of MARK4 rescued the decrease in MDA-MB-
231, A549 and H1299 cell migration, although this was more promi-
nent for the lung cancer cell lines (Fig 4B and Appendix Fig S7C).
MARK4 silencing triggers cell cycle arrest
In addition to the changes in cell motility, regulation of microtubule
dynamics would also be expected to have significant effects on cell
division. We therefore compared the cell cycle distribution between
control-transfected A549 cells and cells silenced for MARK4. This
analysis revealed that MARK4-down-regulated cells accumulated in
the G1 phase of the cell cycle while showing a decrease in DNA
synthesis (Appendix Fig S8A). This was accompanied by an increase
in the levels of p53 as well as its transcriptional target, p21, in
MARK4-silenced cells, suggesting that down-regulating this kinase
induces cell cycle arrest (Appendix Fig S8B). To analyse the speed of
microtubule growth, a plasmid encoding GFP tagged end-binding
protein 3 (EB3) was transfected into A549 cells. This protein binds to
the growing end of the microtubules (MT), and by imaging the move-
ment of the GFP comets produced as the microtubule grows, we were
able to quantify the speed of growth and compare this growth rate
between cells silenced for MARK4 or transfected with a non-targeting
control siRNA. Representative images of the comets for the two condi-
tions can be seen in Appendix Fig S9A. When quantified using ImageJ
and the wrMTrck plug-in, the comet speed was found to be signifi-
cantly higher in cells silenced for MARK4 suggesting an increase in
the rate of tubulin polymerisation (Appendix Fig S9B).
MARK4 expression levels increase during tumorigenesis and are
inversely correlated to patient survival
To assess the clinical relevance of our findings, we first evaluated
the potential of MARK4 as prognostic biomarkers in metastatic
breast and lung cancer patients (Fig 5).
We analysed the overall survival (months) of a cohort of patients
with metastatic lung or breast cancer and correlated this with the
levels of MARK4 mRNA present in their tumours. High levels of
MARK4 mRNA correlated with a lower overall survival in ER-
negative metastatic breast and lung cancer patients, although this
only reached statistical significance in the latter (Fig 5A and B).
Quantitative PCR analysis of a lung cancer cDNA array revealed that
MARK4 mRNA levels are increased in > 50% of tumours as
compared to normal lung tissues (Fig 5C). In agreement with this,
MARK4 protein was detectable in 37% of lung cancer samples,
while it remained undetected in normal lung tissue (Fig 5D). When
subtypes of lung cancer were separated, MARK4 expression was
especially prevalent in adenocarcinoma samples with 53% of cases
for this tumour type showing positive MARK4 staining (Fig 5E). In
addition, comparison of metastatic and primary lesions form the
same patients revealed that MARK4 expression was increased in
secondary as compared to primary tumours in 41% of cases (Fig 5F).
Hence, these data suggest that MARK4 expression increases during
tumorigenesis, impacting negatively on patients’ survival.
Taken together, MARK4 and/or miR-515-5p expression levels
may be relevant prognosis markers in both breast and lung cancer.
miR-515-5p expression is inversely correlated with metastasis in
breast and lung cancer mouse models
In contrast to MARK4, miR-515-5p expression was positively corre-
lated with overall survival in patients with metastatic breast or lung
cancer (Fig 6A–D and Appendix Fig S10A and B). Moreover, in
luminal B breast cancer and in normal breast epithelial cells, miR-
515-5p levels were significantly inversely correlated with MARK4
expression and a similar trend existed in the case of luminal A and
basal breast cancer (Appendix Fig S11). Because the advent of meta-
static disease is one of the main factors that negatively impact on
patients’ survival, we proceeded to measure miR-515-5p levels in
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Figure 3. MARK4 knock-down mimics the effect of miR-515-5p overexpression.
A–C MARK4 siRNA-mediated silencing increases the tubulin cytoskeletal area (A) and reduces random (B) and directed (C) migration in MDA-MB-231 (MDA), A549 and
H1299 cells. (A) Data shown are representative of experiments performed in triplicate. Bar graph represents the average  SEM of n ≥ 50 per technical replicate
with three technical replicates per conditions. Cells were transfected either with siRNA targeting MARK4 (M4) or a non-targeting control (NC) for 48 h before time-
lapse imaging was performed for 18 h (B) or transwell assay for 9 h (C). (B, top panel) Plots show overlays of representative trajectories described. (B, bottom panel)
The migration distance was quantified and represented as the normalised mean  SEM. (C, top panel) Representative field of view from the bottom side of the
transwell membrane. (C, bottom panel) Graphs indicate cell migration expressed as a percentage of the average of migratory cells per field (n = 5 fields per
condition). (B–C) Data are mean of three experiments  SEM. (A–C) P-values were calculated by t-test between the siRNA-transfected and the respective control
condition (***P < 0.001). Scale bar: 200 lm.
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paired primary and metastatic breast cancer patient samples. This
demonstrated a lower mean expression of miR-515-5p in lymph
node metastases compared to their corresponding primary tumours
(Fig 6E), either by comparing the absolute values (Fig 6E) or the
paired values for each patient (Appendix Fig S12).
To evaluate whether changes to the expression of miR-515-5p
directly modulated the metastatic potential of breast and lung cancer
cells, we performed two animal experiments. MDA-MB-231 cells
have previously been used to induce metastatic lesions in nude mice
following inoculation into their mammary fat pads [19]. Using
samples from both primary and metastatic lesions obtained in these
animals, we showed that miR-515-5p levels were down-regulated in
all metastatic lesions regardless of site (lung, bone, brain or adrenal
glands) as compared to the corresponding primary tumour (Fig 6F,
left panel). This was accompanied by a corresponding increase in
MARK4 mRNA levels at the metastatic sites (Fig 6F, right panel).
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Figure 4. MARK4 overexpression rescues the inhibitory effects of miR-515-5p on cell migration.
A, B The indicated cell lines were transfected with either miR515-5p or a non-targeting miR (miR-NC) together with a MARK4 expressing or an empty vector (EV) plasmid
DNA. MARK4 overexpression rescues the inhibition by miR-515-5p of random (A) and directed (B) migration of the indicated cell lines. (A, left panel) Plots show overlays
of representative trajectories described for MDA-MB-231 cells (n = 30). (A, right panel) The migration distance was quantified and represented as the normalised
mean  SEM. (B, left panel) Representative field of view from the bottom side of the transwell membrane for MDA-MB-231. (B, right panel) Graphs indicate cell
migration expressed as a percentage of the average of migratory cells per field (n = 5 fields per condition). Data are mean of three experiments  SEM. P-values were
calculated by t-test between the transfected and the respective control condition (EV+miR-NC) (*P < 0.05; **P < 0.01; ***P < 0.001). Scale bar: 200 lm.
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Interestingly, these changes did not necessarily extend to other
miR-515-5p targets, as NRAS expression levels did not vary signifi-
cantly between primary and metastatic lesions (Appendix Fig S13A)
and PI3KC2B expression was only significantly up-regulated in the
metastatic cells isolated from brain and adrenal glands
(Appendix Fig S13B). Hence, confirming the results of the rescue
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Figure 5. MARK4 expression levels increase during tumorigenesis and correlate poor patient prognosis.
A, B Overall survival of ER-negative metastatic breast cancer (n = 226) (A) and lung adenocarcinoma (n = 719) (B) patients according to MARK4 mRNA levels found in
their tumours was represented using the Kaplan–Meier plotter [25].
C A cDNA array for 24 matched lung cancers and surrounding normal tissue was analysed for MARK4 expression. Expression levels from tumours were normalised to
their respective normal control and the percentage of cases for the indicated fold expression in the tumour represented as a pie chart.
D–F MARK4 protein expression was determined by histoimmunochemistry in (D–E) a tissue microarray comprising 90 lung tumour and 10 normal lung samples or (F) a
home-made tissue microarray comprising 100 matched cases of primary and metastatic tumours. (D–E) The percentage of positivity for MARK4 staining in lung
tumours versus normal lung samples (D) or in lung tumours according to their histological subtypes (E) is represented. (F) The percentage of cases with increased,
decreased or unchanged levels of MARK4 in metastatic lesions as compared to the corresponding primary tumours is represented.
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experiments, these data suggest that MARK4 may be the essential
target regulating metastasis downstream of miR-515-5p (Fig 4A and
B). While the preceding results suggested that decreased miR-515-5p
expression was associated with the onset of metastasis, they did not
demonstrate this change to be a causal phenomenon. Therefore, we
wished to examine whether directly changing levels of this miRNA
could modulate tumour cells colonisation in vivo. A549 cells stably
expressing a luciferase reporter gene were transfected with or with-
out miR-515-5p and the cells injected 72 h later into SCID mice
through the tail vein. The animals were then monitored by whole-
animal imaging following the administration of luciferin at 4 days
and 4 weeks following the injection (Fig 6G, left panel). The biolu-
minescent signal was then quantified and plotted to show the extent
of the metastatic burden (Fig 6G, right panel). This analysis
revealed that while cells transfected with a non-targeting miRNA
mimetic (miR-NC) efficiently colonised the mice, miR-515-5p-trans-
fected cells failed to establish tumours in the injected animals
(Fig 6G). Hence, changes in miR-515-5p levels alone are sufficient
to modulate the metastatic potential of cancer cells.
MARK4 silencing prevents metastatic lung colonisation of
A549 cells
We next tested whether MARK4 silencing alone could reproduce the
effects of miR-515-5p expression on the metastatic behaviour of
A549 cells. A549-Luc cells were transfected with MARK4 siRNAs or
a non-targeting sequence and injected 48 h later into SCID mice
through the tail vein. Four weeks later, the mice were sacrificed and
their lungs extracted and fixed prior to immunohistochemical
staining for luciferase expression. As an internal positive control,
we performed the same experiments using cells overexpressing
miR-515-5p or a corresponding non-targeting sequence. Figure 7A
shows that, 4 weeks following tail vein injection, cells transfected
with non-targeting siRNA had colonised the lungs of the animals as
revealed by the presence of luciferase-positive cells either as single
cells (Fig 7A, upper panels) or as tight tumours (Fig 7A, lower
panels). Quantification of the percentage of area of the fields of view
covered by luciferase-positive cells revealed that MARK4 silencing,
just as miR-515-5p overexpression, impaired lung colonisation by
A549 cells (Fig 7B). These data further confirm that MARK4, as a
downstream target of miR-515-5p, controls the invasive potential of
cancer cells.
Discussion
Having previously demonstrated the role of miR-515-5p as an ER-
positive breast cancer tumour suppressor [11], here we show that
miR-515-5p inhibits cell migration via its targeting of MARK4.
Initially, we investigated the role of miR-515-5p in cell migration
because we observed rearrangement of the tubulin cytoskeleton in
MCF7 and MDA-MB-231 cells that overexpressed miR-515-5p
(Fig 1A). We previously demonstrated that ERa suppresses miR-
515-5p expression by direct interaction with its promoter, indicating
a link between this miRNA and oestrogen signalling [11]. Interest-
ingly, the expression of miR-515-5p is lower in MCF7 epithelial-like
cells than in MDA-MB-231 which are more mesenchymal-like. This
suggests that ERa is not the only transcription factor regulating miR-
515-5p expression, but additional regulators modulate its levels in
association with the mesenchymal phenotype. Both MCF7 and
MDA-MB-231 cells appeared enlarged with a loss of polarity that is
often associated with non-migratory cells. This change did not
correlate with the onset of cell death downstream of this miRNA
[11] indicating that the effects of miR-515-5p on cell morphology
may be caused by distinct targets and, consequently, through
different signalling pathways. Additionally, because MDA-MB-231 is
an ER-negative breast cancer cell line, we propose that the oestrogen
receptor-a is not involved in these effects. Moreover, miR-515-5p
caused similar cytoskeletal changes in non-small cell lung cancer
(NSCLC) cells, highlighting a common function of this miRNA
across tumour types.
As altered cytoskeletal dynamics and cell polarity are known to
influence cell motility, we investigated the effect of miR-515-5p on
cell migration. Consistent with the morphological changes (Fig 1A
and Appendix Figs S2 and S6C), miR-515-5p inhibited both random
and directional cell migration in both breast and lung cancer cell
lines (Fig 1B and C and Appendix Fig S6B). In order to ascertain the
mechanism through which miR-515-5p altered cell morphology and
migration and identify its gene targets, we performed an RNA-seq
analysis using RNA obtained from miR-515-5p-transfected MCF7
and MDA-MB-231 cells. We identified 5 transcripts down-regulated
upon miR-515-5p overexpression: NRAS, FZD4, CDC42BPA,
PIK3C2B and MARK4 (Fig 2A), and these were validated by qPCR
(Fig 2B and C). These transcripts have been described as being
involved in cell migration and are predicted by TargetScan to
be directly targeted by miR-515-5p [6,12–15]. Furthermore, we
Figure 6. miR-515-5p expression is inversely correlated with breast cancer metastasis and correlates with good patient prognosis.
A–D Low expression of miR-515-p is linked to survival in both lung and breast cancer. (A) Survival analysis of miR-515-5p from 195 lung adenocarcinoma samples from
the TCGA. (B) Survival analysis of miR-515-p from 34 lung squamous cell carcinoma from the TCGA [18]. (C) Survival analysis of miR-515-5p from 60 breast cancer
samples from the Lyng Ditzel Breast Study (GSE37405). (D) Survival analysis of miR-515-5p from 33 breast cancer from the GSE7405 Breast study. Analysis and plot
were obtained with SurvMicro http://bioinformatica.mty.itesm.mx:8080/Biomatec/Survmicro.jsp for (A–C) and with MIRUMIR for (D).
E Comparison of miR-515-5p expression in 18 primary and matched metastatic lesions from breast cancer patients. miR-515-5p levels were quantified by TaqMan
qRT–PCR. Absolute values were normalised to U6 snRNA values and displayed as a dot-plot. Bar: mean; whiskers, SEM.
F MDA-MB-231 cells were inoculated into the mammary fat pads of nude mice and allowed to form metastatic deposits [19]. miR-515-5p and MARK4 levels were
then determined in the primary and indicated secondary lesions. Data are average  SEM of technical triplicates.
G Luciferase-expressing A549 cells overexpressing miR-515-5p or a non-targeting control (miR-NC) were injected in the tail vein of SCID mice and the development of
tumour burden monitored by whole-animal imaging in response to luciferin administration at week 1 and week 4 following injection. (G, left panel) Representative
imaging of the same animals for the indicated conditions at week 1 and week 4. Dots colors correspond to luminescence counts as per the scale on the right. (G,
right panel) The emitted photons were quantified and the signals normalised to the corresponding readings at week 1. Data represented are representative of three
independent experiments.
Data information: (E–G) P-values were calculated by t-test (*P < 0.05; **P < 0.01; ***P < 0.001).
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Figure 7. miR-515-5p overexpression or siRNA-mediated MARK4 silencing prevents A549 cell metastasis to the lung.
A549-Luc cells transfected either with miR-515-5p precursor (miR), siRNAs to MARK4 (siMARK4) or the corresponding control sequences (C and NT, respectively) were injected
in SCID mice through the tail vein. Four weeks later, the mice were sacrificed and their lungs extracted and fixed prior to staining for luciferase expression.
A Representative pictures showing the presence of A549-Luc cells in the lungs of NT mice either as single cells (upper panel) or as a tumour mass (lower panel). Scale bar:
100 lm.
B Percentage of the area covered by tumour cells on randomly observed fields of views. Quantification was performed using Photoshop CS4. Each spot corresponds to
quantification of an individual 1 mm × 1.5 mm field. Transversal bar: median; Statistics: Student’s t-test. *P ≤ 0.05.
C Schematic summary. Increase in MARK4 expression is the main reason for miR-515-5p-down-regulated cells to show increased metastatic abilities in breast and lung
cancer. The down-regulation of miR-515-5p de-represses MARK4 translation in individual cells from the primary tumour promoting their metastatic dissemination
through the blood or lymphatic circulation and reducing patients’ survival.
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validated this using luciferase report assays that demonstrated that
miR-515-5p interacts directly with the 30 UTR of NRAS, PIK3C2B and
MARK4 (Fig 2E and F) and showed the same targets to be down-
regulated by miR-515-5p in NSCLC cells (Fig 2D). We focussed
on investigating whether MARK4 down-regulation mediated the
migratory effects of miR-515-5p because this target was most
dramatically decreased by miR-515-5p overexpression in breast
cancer (Fig 2B and C) and had previously been involved in micro-
tubule dynamics [6]. TargetScan predicted two different sites of
miR-515-5p interaction in MARK4 30 UTR and using site directed
mutagenesis coupled with luciferase assay and overexpression of
miR-515-5p mimic we demonstrated that miR-515-5p post-transcrip-
tionally repress MARK4 expression interacting with both sites
(Appendix Fig S5). Interestingly, MARKs phosphorylate micro-
tubule-associated proteins (MAPs) on their microtubule-binding
domain, disrupting their binding to tubulin and the dynamics of
microtubules. In agreement with our hypothesis, silencing MARK4
mimics the changes in the tubulin cytoskeleton and inhibition of cell
migration obtained downstream of miR-515-5p overexpression in all
cell lines tested (Fig 3A–C and Appendix Fig S6C). This correlated
with an increase in the rate of microtubule polymerisation down-
stream of MARK4 silencing (Appendix Fig S9). MARK activity has
been shown to be regulated by a number of different processes
including phosphorylation, ubiquitination and interaction with inhi-
bitory proteins [20]. However, to our knowledge, this is the first
report of the regulation of a MARK family member by a micro-RNA.
To test our hypothesis that MARK4 down-regulation was the
mechanism through which miR-515-5p affected breast cancer
cell migration, we tested whether overexpressing MARK4 in
miR-515-5p-transfected cells could rescue the reduced cell motility.
In agreement with our hypothesis, MARK4 overexpression rescued
the effect of miR-515-5p on random cell migration (Fig 4A and B).
However, increased MARK4 expression did not completely rescue
the effect of miR-515-5p overexpression on directional migration in
two out of the three cell lines tested (Fig 5A and B). This may be
due to the additional factors regulating directional cell migration,
such as sensing of growth factor gradient and cell deformability that
may require input from additional miR-515-5p targets. However,
since rescue of both types of migration was almost total (80–100%),
our data suggest that MARK4 down-regulation is probably the main
mediator of cell migration regulation by miR-515-5p.
We wished to assess whether these in vitro finding showed any
clinical relevance and quantified miR-515-5p in tissues from breast
cancer patients. We found that miR-515-5p expression was signifi-
cantly reduced in lymph nodes metastasis compared to primary
tumours derived from the same breast cancer patients (Fig 6E and
Appendix Fig S12). Moreover, we found that low miR-515-5p
expression correlated with poorer survival in breast and lung cancer
(Fig 6A–D). The opposite correlation existed for MARK4 expression,
with high expression of this kinase correlating with poorer survival
in these two cancer types (Fig 5A and B). Moreover, MARK4 was
clearly up-regulated during lung tumorigenesis and further
increased in metastatic lesions in over 40% of cases (Fig 5C–F).
MARK4 has previously been shown to be up-regulated in glioma
and hepatocellular carcinomas [1,2] and associated with Wnt-
induced tumorigenesis in the prostate [21]. Nevertheless, this is the
first report of its overexpression during lung tumorigenesis and of
its particular association with the metastatic process. This link
between changes in MARK4 expression and clinical metastatic
disease was supported by our experimental data using animal
models. Indeed, we quantified MARK4 levels in metastatic lesions
obtained following the inoculation of MDA-MB-231 cells into the
mammary fat pads of nude mice. MARK4 mRNA levels, but not
those for NRAS and PI3KC2B, were increased in metastatic as
compared to primary lesions in these animals (Fig 6F and
Appendix Fig S13). Interestingly, we confirmed the opposite correla-
tion for miR-515-5p with the levels of this miRNA being down-
regulated in metastatic lesions (Fig 6F). These data reinforce the
notion that MARK4 is the main miR-515-5p target regulating cell
migration and metastasis. However, while these data suggested that
the miR-515-5p/MARK4 axis may be regulated in the context of
metastatic disease, it did not draw a direct link between miR-515-5p
expression levels and the onset of metastasis. Hence, we performed
an experiment to assess how overexpression of this miRNA would
influence to ability of cancer cells to colonise SCID mice following
tail vein injection. Contrary to cells transfected with a non-targeting
control, miR-515-5p-overexpressing A549 cells failed to establish
tumours in these animals (Fig 6G) demonstrating the direct ability
of miR-515-5p to regulate the metastatic abilities of cancer cells. In
addition, similarly to miR-515-5p overexpression, MARK4 silencing
prevented lung colonisation by A549 cells (Fig 7A and B), showing
that the reduction of invasive potential observed in vitro following
MARK4 down-regulation extends to the in vivo setting.
In summary, we demonstrate here that miR-515-5p overexpres-
sion inhibits cell migration by down-regulating MARK4 mRNA
levels in both breast and lung cancer (Fig 7C), suggesting the impor-
tance of miR-515-5p/MARK4 mechanism across different cancer
types. We showed that miR-515-5p and MARK4 levels are signifi-
cantly down-regulated/up-regulated in metastatic breast cancer
tissues compared to primary tumour tissues, respectively, demon-
strating the clinical relevance of our findings and indicating in the
future that perhaps a miR-515-5p-based therapy as possible treat-
ment to prevent the migration of cancer cells from the primary
tumour. Finally, the correlation between miR-515-5p/MARK4
expression and the outcome of metastatic breast and lung cancer
suggests the use of miR-515-5p and MARK4 as prognostic molecular
biomarkers for metastatic cancer patients. Also, as MARK4-specific
inhibitors have now been developed [21], our data suggest that
these molecules may be useful in the clinic to prevent metastatic
dissemination of lung, breast and possibly other cancers.
Materials and Methods
Cell lines
The human MCF7, MDA-MB-231, MDA-157, A549 and H1299 were
obtained from ATTC (Manassas, VA, USA) and maintained in
Dulbecco’s modified Eagle’s medium (Gibco) supplemented
with 10% foetal bovine serum (Gibco), 100 U/ml penicillin and
100 mg/ml streptomycin at 37°C with 5% CO2.
Luciferase assay
MCF7 and MDA-MB-231 cells were plated in 24-well plates and were
allowed to adhere and grow overnight at 37°C with 5% CO2. The
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following day, the cells were co-transfected with pLightSwitch_3UTR
GoClone vectors, and the indicated 50 nM of miRNA precursors (pre-
miR mimics, Ambion) using LipofectamineTM 2000 (Invitrogen). The
sequences for the 30 UTRs used were those for the following Gene IDs:
PIK3C2B Gene ID: 5287; NRAS Gene ID: 4893; MARK4 Gene ID:
57787. After 24 h, cells were lysed using a passive lysis buffer
(Promega, Southampton, UK) and processed with the LightSwitch
Assay System (Switchgear Genomics Menlo Park CA, USA) according
to manufacturer’s instructions. Luciferase activity detection was
performed using a GLOMAX 96 Microplate luminometer (Promega).
MicroRNAs, siRNAs and plasmids transfection
Cells were plated and allowed to adhere and grow overnight at 37°C
with 5% CO2. The following day, cells were transfected with 50 nM
of pre-miRs (Ambion) or 30 nM of siRNAs (Dharmacon,
Appendix Table S1) using the HiPerFect transfection reagent (Qia-
gen) according to the manufacturer’s instructions. Twenty-four
hours later, cells were transfected with control (pCDNA 3.0) or HA-
MARK4 plasmid (kind gift from Dr. Drewes [6]) using Attractene
and according to the manufacturer instructions.
Immunofluorescence
Cells were fixed in 4% PFA at 37°C for 15 min, washed in PBS and
then blocked in 3% BSA at room temperature for 1 h. Actin
cytoskeleton was stained with Alexa 488 Phalloidin (Invitrogen),
microtubules with an anti-beta-tubulin antibody (Sigma) and
nuclear DNA visualised using DAPI (Invitrogen) at 4°C overnight.
The following day, the stained cells were washed twice with PBS,
secondary TRITC-antibody added for 1 h and the cells washed thrice
with PBS. Images were acquired using an ImageXpress High Content
Screening microscope (Molecular Devices), 48 fields per condition.
Cellular circularity factor
Actin cytoskeleton staining of miR-515-5p and control miRVANA
transfected cells was performed using Alexa 488 Phalloidin as
described above, and fluorescent microscopy images for 10 fields
per condition were acquired on an ImageXpress screening micro-
scope (Molecular Devices). The cellular circularity factor was calcu-
lated for individual cells in ImageJ following the formula 4pA/P2,
where A is the cell area and P is the cell perimeter.
Cell cycle analysis by FACS
The Click-iT EdU cell proliferation assay kit (Life Technologies) was
used to assess changes in cell cycle profile. Following the desired
treatment, before harvesting the cells, 5-ethynyl-20-deoxyuridine
(EdU) was added to the culture medium (10 lM) for 1 h, at 37°C
10% CO2, to allow for incorporation into the DNA during active DNA
synthesis. Cells were then trypsinised, pelleted and washed with 1%
(w/v) BSA in PBS. About 100 ll of Click-iT fixative was added and
incubated at room temperature, in the dark, for 15 min. The cells
were again washed with 1% BSA PBS and permeabilised with 100 ll
of 1× Click-iT saponin-based permeabilisation buffer/wash reagent
for 15 min. As per the manufacturer’s instructions, 1× Click-iT
reaction cocktail was prepared (for 1 ml: 100 ll 1× Click-iT EdU
buffer additive, 875 ll PBS, 20 ll CuSO4, 5 ll Alexa Fluor
 488
azide) and 500 ll added to the cells at room temperature for 30 min
in the dark. Cell pellets were then washed with 1× Click-iT saponin-
based permeabilisation and wash reagent once before being
re-suspended in 500 ll 1× Click-iT saponin-based permeabilisation
and wash reagent. The stained cells were analysed using the FACS-
Diva software v6.12 on a FACSCanto A flow cytometer. Data were
analysed using FlowJo v7.6.5 (Tree Star Inc).
Cell tracking assay
1 × 103 cells per well were plated in black, flat and clear bottomed 96-
well plates (BD Biosciences). Time-lapse imaging was performed for
18 h (1 image/10 min) using a motorised-staged environment-
controlled ImageXpress high content screening microscope powered by
MetaXpress 2.0 (Molecular Devices). Two sites were acquired per well,
and each condition was present in triplicate. To quantify the degree of
migration, a minimum of 30 cells per condition were tracked using
MetaXpress Track Points application. Tracks were analysed using a
previously publishedMathematica (Wolfram Research) notebook [22].
Boyden chamber assay
For transwell migration assays, 5 × 104 cells were seeded at the top
uncoated membranes with 8.0-lm pores (BD Biosciences). Cells
were plated in serum-free medium and allowed to migrate towards
a complete growth medium for 8 h. The cells on the bottom part of
the filter were then stained using crystal violet. Stained cells were
then imaged using Olympus BX51 microscope. Directional migration
was quantified by cell counting using ImageJ [23].
Microtubule comet imaging and analysis
To analyse the speed of microtubule growth, a plasmid encoding
GFP-tagged end-binding protein 3 (EB3) was used. The plasmid was
transfected into A549 cells 24 h before the cells were re-plated into
8-well chamber slides (PAA laboratories). During re-plating, cells
were reverse transfected with siRNA against the MARK4 or a non-
targeting control siRNA. Cells were then incubated for 24 h at 37°C
10% CO2. The movement of the EB3-GFP comets was imaged in indi-
vidual cells using a Zeiss LSM-780 inverted microscope (Zeiss) using
the Zen Black software (Zeiss) and a 40×magnification lens with one
image acquired per sec for a total of 2 min on a 1.3-lm z-section. A
total of 12 cells per condition were imaged in each independent repeat
experiment. Comets were tracked using FIJI ImageJ (NIH, USA) and
the plug-in wrMTrck (J. Pedersen) to determine comets’ speed.
RNA-Seq and ChIP-Seq analysis
Two micrograms of total RNA from each sample was used to
produce cDNA libraries from polyA enriched RNA using the
True-Seq RNA preparation kit (Illumina Inc., San Diego, CA, USA)
according to the manufacturer instructions. Paired end sequences
(reads) 100 nt in length were then generated using a HiSeq 2000
instrument (Illumina). Fastq files containing the sequenced reads,
obtained at the end of the sequencing, were mapped to the Univer-
sity of California at Santa Cruz (UCSC) human genome (hg19
assembly) with TopHat version 1.4.1 (http://tophat.cbcb.umd.edu),
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using default settings. The mapped bam files obtained at the end of
the runs were then analysed using Cufflinks version 2.1.0 (http://
cufflinks.cbcb.umd.edu) for RNA quantification and analysis. The
RNA-seq raw data have been deposited in the ENA database with
accession number PRJEB11884.
MicroRNAs and mRNA expression
RNA was isolated using TRIzol reagent according to the manufac-
turer instructions. MicroRNA levels were quantified using TaqMan
MicroRNA Reverse Transcription kit (Applied Biosystems), TaqMan
2× Universal PCR Master Mix No AmpErase UNG (Applied Biosys-
tems) and has-pre-miR-515-5p TaqMan primers (Applied Biosys-
tems). To analyse mRNA expression, both cDNA conversion and
qPCR amplification were performed as recommended by Applied
Biosystems using the High-Capacity cDNA Reverse Transcription Kit
and Fast SYBR Green Master Mix, respectively. The primers used
for NRAS, PI3KC2B, FZD4, CDC42BPA, MARK4 and GAPDH are
detailed in Appendix Table S2.
Tumour tissues—microRNA expression
MicroRNA expression analysis in formalin-fixed paraffin-embedded
(FFPE) was approved by a UK national research ethics committee
(London; 07/Q0401/20) and by Imperial College Healthcare NHS
Trust. We prospectively measured miR-515-5p expression in
primary BCs and corresponding lymph node metastasis from
patients with lymph node positive BC. Between January 2008 and
February 2010, we obtained primary breast tumours and corre-
sponding lymph node metastases at Imperial College Healthcare
NHS Trust, London, UK. All samples were formalin-fixed and paraf-
fin-embedded. Clinico-pathological information about the patients is
provided in Appendix Table S3.
Lung cancer versus normal lung cDNA arrays
The levels for MARK4 mRNA were determined in the HLRT104
TissueScan cDNA array (Origene) containing 24 lung cancer and
matching normal lung samples and were analysed by using the Fast
SYBR Green PCR Master Mix and 7900HT Real-time PCR System
(Applied Biosystems). The housekeeping genes hypoxanthine phos-
phoribosyl-transferase (HPRT) and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were used as reference genes to normalise
the expression of target genes. Primers used are presented in
Appendix Table S2. Analysis of relative gene expression was carried
out using the qbasePLUS 2.1 software (Biogazelle).
Immunohistochemistry
The lung cancer tissue microarray (TMA) BC041114 containing 90
cases of lung carcinoma and 10 normal tissue samples was purchased
from Insight Biotechnology Limited (UK). For the syngeneic primary
tumour/metastasis tissue microarray, 100 lung cancer cases (Ethic
Ref: 06/Q0406/154) were considered suitable on the basis of
histotype confirmation and immunostaining for pan-cytokeratin
MNF116 and vimentin. Tissue microarrays were prepared by obtaining
three 1-mm cores from the most representative and better preserved
areas of the tumours and re-embedded in microarray blocks.
TMAs were stained using a primary antibody against MARK4
(Sigma-Aldrich, SAB1300394) used at a 1:50 dilution. A semiquanti-
tative scoring of the histochemical staining was used as previously
published by us [24]. The intensity of the staining was given a score
of 0, negative, to 3, strongly positive. The percentage coverage of
the staining was assessed and scored between 0 and 100%. Scores
were multiplied together to give a range of possible scores between
0 and 300. The cores were all scored bind of all clinical data. The
TMA data for each array were analysed separately then appropri-
ately grouped to assess any changes in MARK4 protein levels in
tissue within different stage, grade and classification of tumours.
Animal experiment
A549 cells stably expressing luciferase (A549-Luc-C8, Xenogen)
were transfected with 50 nM pre-miR-515-5p or miRVANA control
using HiPerFect (Qiagen) or with 20 nM MARK4 or non-targeting
siRNAs. Forty-eight hours later, 1 × 106 cells were injected in the
tail vein of SCID mice (eight animals per group) and mice subjected
to whole-body imaging under anaesthesia, at 1 and 4 weeks, follow-
ing tail vein administration of luciferin or sacrificed at 4 weeks prior
to their lungs being extracted, fixed in 70% ethanol, paraffin-
embedded and stained for luciferase expression by immunohisto-
chemistry (anti-luciferase antibody, sc-32896 from Santa Cruz
Biotechnology). For the latter, images were acquired under micro-
scopic observation and at ×10 and ×40 magnification. The percent-
age of field of view area covered by luciferase staining in 10×
magnification images was quantified under FIJI-ImageJ. Animal
experiments were carried out according to the National Guidelines
for Experimental Animal Welfare (MOST, P.R. China, 2006) in a SPF
facility certified by the Hubei Provincial Office of Science and
Technology (SYXKE 20090051).
Statistical analysis
All data in the figures are presented as the mean  standard error
of mean (SEM) and assessed by using one-way ANOVA analysis
followed by a Tukey’s test (95% confidence) for multiple compar-
isons (SPSS version 17). P-value of < 0.05 is considered statistically
significant.
Expanded View for this article is available online.
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